AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification. (2021)
Attributed to:
BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ctarc.2020.100218
PubMed Identifier: 33516656
Publication URI: http://europepmc.org/abstract/MED/33516656
Type: Journal Article/Review
Volume: 28
Parent Publication: Cancer treatment and research communications
ISSN: 2468-2942